nach oben

Diabetologia

Erschienen in:

01.05.2014 | Article

In vivo activation of the PI3K–Akt pathway in mouse beta cells by the EGFR mutation L858R protects against diabetes

verfasst von: Elina Hakonen, Jarkko Ustinov, Décio L. Eizirik, Hannu Sariola, Päivi J. Miettinen, Timo Otonkoski

Erschienen in: Diabetologia | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

EGF receptor (EGFR) signalling is required for normal beta cell development and postnatal beta cell proliferation. We tested whether beta cell proliferation can be triggered by EGFR activation at any age and whether this can protect beta cells against apoptosis induced by diabetogenic insults in a mouse model.

Methods

We generated transgenic mice with doxycycline-inducible expression of constitutively active EGFR^L858R (CA-EGFR) under the insulin promoter. Mice were given doxycycline at various ages for different time periods, and beta cell proliferation and mass were analysed. Mice were also challenged with streptozotocin and isolated islets exposed to cytokines.

Results

Expression of EGFR ^L858R led to increased phosphorylation of EGFR and Akt in pancreatic islets. CA-EGFR expression during pancreatic development (embryonic day [E]12.5 to postnatal day [P]1) increased beta cell proliferation and mass in newborn mice. However, CA-EGFR expression in adult mice did not affect beta cell mass. Expression of the transgene improved glycaemia and markedly inhibited beta cell apoptosis after a single high dose, as well as after multiple low doses of streptozotocin. In vitro mechanistic studies showed that CA-EGFR protected isolated islets from cytokine-mediated beta cell death, possibly by repressing the proapoptotic protein BCL2-like 11 (BIM).

Conclusions/interpretation

Our findings show that the expression of CA-EGFR in the developing, but not in the adult pancreas stimulates beta cell replication and leads to increased beta cell mass. Importantly, CA-EGFR protects beta cells against streptozotocin- and cytokine-induced death.

Nur mit Berechtigung zugänglich

Eizirik DL, Mandrup-Poulsen T (2001) A choice of death—the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 44:2115–2133PubMedCrossRef

Thomas HE, McKenzie MD, Angstetra E et al (2009) Beta cell apoptosis in diabetes. Apoptosis 14:1389–1404PubMedCrossRef

Gurzov EN, Eizirik DL (2011) Bcl-2 proteins in diabetes: mitochondrial pathways of β-cell death and dysfunction. Trends Cell Biol 21:424–431PubMedCrossRef

Herold KC, Vignali DAA, Cooke A, Bluestone JA (2013) Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol 13:243–256PubMedCrossRef

Schlessinger J, Ullrich A (1992) Growth factor signaling by receptor tyrosine kinases. Neuron 9:383–391PubMedCrossRef

Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7:505–516PubMedCrossRef

Kritzik MR, Krahl T, Good A et al (2000) Expression of ErbB receptors during pancreatic islet development and regrowth. J Endocrinol 165:67–77PubMedCrossRef

Huotari M-A, Miettinen PJ, Palgi J et al (2002) ErbB signaling regulates lineage determination of developing pancreatic islet cells in embryonic organ culture. Endocrinology 143:4437–4446PubMedCrossRef

Miettinen PJ, Huotari M, Koivisto T et al (2000) Impaired migration and delayed differentiation of pancreatic islet cells in mice lacking EGF-receptors. Development 127:2617–2627PubMed

10.

Miettinen PJ, Ustinov J, Ormio P et al (2006) Downregulation of EGF receptor signaling in pancreatic islets causes diabetes due to impaired postnatal beta-cell growth. Diabetes 55:3299–3308PubMedCrossRef

11.

Cras-Meneur C, Elghazi L, Czernichow P, Scharfmann R (2001) Epidermal growth factor increases undifferentiated pancreatic embryonic cells in vitro: a balance between proliferation and differentiation. Diabetes 50:1571–1579PubMedCrossRef

12.

Miettinen P, Ormio P, Hakonen E et al (2008) EGF receptor in pancreatic beta-cell mass regulation. Biochem Soc Trans 36:280–285PubMedCrossRef

13.

Elghazi L, Bernal-Mizrachi E (2009) Akt and PTEN: beta-cell mass and pancreas plasticity. Trends Endocrinol Metab 20:243–251PubMedCrossRef

14.

Choi SH, Mendrola JM, Lemmon MA (2007) EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer. Oncogene 26:1567–1576PubMedCrossRef

15.

Shan Y, Eastwood MP, Zhang X et al (2012) Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization. Cell 149:860–870PubMedCrossRef

16.

Nir T, Melton D, Dor Y (2007) Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 117:2553–2561PubMedCrossRefPubMedCentral

17.

Politi K, Zakowski MF, Fan P-D, Schonfeld EA, Pao W, Varmus HE (2006) Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 20:1496–1510PubMedCrossRefPubMedCentral

18.

Hakonen E, Ustinov J, Mathijs I et al (2011) Epidermal growth factor (EGF)-receptor signalling is needed for murine beta cell mass expansion in response to high-fat diet and pregnancy but not after pancreatic duct ligation. Diabetologia 54:1735–1743PubMedCrossRef

19.

Alanentalo T, Asayesh A, Morrison H et al (2007) Tomographic molecular imaging and 3D quantification within adult mouse organs. Nat Methods 4:31–33PubMedCrossRef

20.

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods 25:402–408PubMedCrossRef

21.

Liu D, Pavlovic D, Chen MC, Flodström M, Sandler S, Eizirik DL (2000) Cytokines induce apoptosis in beta-cells isolated from mice lacking the inducible isoform of nitric oxide synthase (iNOS−/−). Diabetes 49:1116–1122PubMedCrossRef

22.

Flodström M, Tyrberg B, Eizirik DL, Sandler S (1999) Reduced sensitivity of inducible nitric oxide synthase-deficient mice to multiple low-dose streptozotocin-induced diabetes. Diabetes 48:706–713PubMedCrossRef

23.

Wicksteed B, Brissova M, Yan W et al (2010) Conditional gene targeting in mouse pancreatic ß-cells: analysis of ectopic Cre transgene expression in the brain. Diabetes 59:3090–3098PubMedCrossRefPubMedCentral

24.

Irmer D, Funk JO, Blaukat A (2007) EGFR kinase domain mutations—functional impact and relevance for lung cancer therapy. Oncogene 26:5693–5701PubMedCrossRef

25.

Lenzen S (2008) The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia 51:216–226PubMedCrossRef

26.

Like AA, Rossini AA (1976) Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 193:415–417PubMedCrossRef

27.

Eizirik DL, Colli ML, Ortis F (2009) The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol 5:219–226PubMedCrossRef

28.

Sandberg JO, Andersson A, Eizirik DL, Sandler S (1994) Interleukin-1 receptor antagonist prevents low dose streptozotocin induced diabetes in mice. Biochem Biophys Res Commun 202:543–548PubMedCrossRef

29.

Moore F, Naamane N, Colli ML et al (2011) STAT1 is a master regulator of pancreatic β-cell apoptosis and islet inflammation. J Biol Chem 286:929–941PubMedCrossRefPubMedCentral

30.

Wang H, Gambosova K, Cooper ZA et al (2010) EGF regulates survivin stability through the Raf-1/ERK pathway in insulin-secreting pancreatic β-cells. BMC Mol Biol 11:66PubMedCrossRefPubMedCentral

31.

Teta M, Long S, Wartschow L, Rankin M, Kushner J (2005) Very slow turnover of beta-cells in aged adult mice. Diabetes 54:2557–2567PubMedCrossRef

32.

Meier JJ, Butler AE, Saisho Y et al (2008) Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. Diabetes 57:1584–1594PubMedCrossRefPubMedCentral

33.

Zeng N, Yang K-T, Bayan J-A et al (2013) PTEN controls β-cell regeneration in aged mice by regulating cell cycle inhibitor p16(ink4a.). Aging Cell 12:1000–1011PubMedCrossRef

34.

Bernal-Mizrachi E, Wen W, Stahlhut S, Welling CM, Permutt MA (2001) Islet beta cell expression of constitutively active Akt1/PKB alpha induces striking hypertrophy, hyperplasia, and hyperinsulinemia. J Clin Invest 108:1631–1638PubMedCrossRefPubMedCentral

35.

Tuttle RL, Gill NS, Pugh W et al (2001) Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKBalpha. Nat Med 7:1133–1137PubMedCrossRef

36.

Elghazi L, Weiss AJ, Barker DJ et al (2009) Regulation of pancreas plasticity and malignant transformation by Akt signaling. Gastroenterology 136:1091–1103PubMedCrossRefPubMedCentral

37.

Ji H, Li D, Chen L et al (2006) The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9:485–495PubMedCrossRef

38.

Sordella R, Bell DW, Haber DA, Settleman J (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305:1163–1167PubMedCrossRef

39.

Oh YS, Shin S, Lee Y-J, Kim EH, Jun H-S (2011) Betacellulin-induced beta cell proliferation and regeneration is mediated by activation of ErbB-1 and ErbB-2 receptors. PLoS ONE 6:e23894PubMedCrossRefPubMedCentral

40.

Yamamoto H, Uchigata Y, Okamoto H (1981) Streptozotocin and alloxan induce DNA strand breaks and poly(ADP-ribose) synthetase in pancreatic islets. Nature 294:284–286PubMedCrossRef

41.

Kantwerk-Funke G, Burkart V, Kolb H (1991) Low dose streptozotocin causes stimulation of the immune system and of anti-islet cytotoxicity in mice. Clin Exp Immunol 86:266–270PubMedCrossRefPubMedCentral

42.

Cnop M, Welsh N, Jonas J-C, Jörns A, Lenzen S, Eizirik DL (2005) Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 54(Suppl 2):S97–S107PubMedCrossRef

43.

Barthson J, Germano CM, Moore F et al (2011) Cytokines tumor necrosis factor-α and interferon-γ induce pancreatic β-cell apoptosis through STAT1-mediated Bim protein activation. J Biol Chem 286:39632–39643PubMedCrossRefPubMedCentral

44.

Santin I, Moore F, Colli ML et al (2011) PTPN2, a candidate gene for type 1 diabetes, modulates pancreatic β-cell apoptosis via regulation of the BH3-only protein Bim. Diabetes 60:3279–3288PubMedCrossRefPubMedCentral

45.

Nogueira TC, Paula FM, Villate O et al (2013) GLIS3, a susceptibility gene for type 1 and type 2 diabetes, modulates pancreatic beta cell apoptosis via regulation of a splice variant of the BH3-only protein Bim. PLoS Genet 9:e1003532PubMedCrossRefPubMedCentral

46.

Ley R, Ewings KE, Hadfield K, Cook SJ (2005) Regulatory phosphorylation of Bim: sorting out the ERK from the JNK. Cell Death Differ 12:1008–1014PubMedCrossRef

47.

Qi X-J, Wildey GM, Howe PH (2006) Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function. J Biol Chem 281:813–823PubMedCrossRef

48.

Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ (2000) Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 10:1201–1204PubMedCrossRef

49.

Gong Y, Somwar R, Politi K et al (2007) Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med 4:e294PubMedCrossRefPubMedCentral

50.

Costa DB, Halmos B, Kumar A et al (2007) BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 4:1669–1679PubMedCrossRef

Titel: In vivo activation of the PI3K–Akt pathway in mouse beta cells by the EGFR mutation L858R protects against diabetes
verfasst von: Elina Hakonen
Jarkko Ustinov
Décio L. Eizirik
Hannu Sariola
Päivi J. Miettinen
Timo Otonkoski
Publikationsdatum: 01.05.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Diabetologia / Ausgabe 5/2014
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-014-3175-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Eingreifen von Umstehenden rettet vor Erstickungstod!

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2014

TIAM1–RAC1 signalling axis-mediated activation of NADPH oxidase-2 initiates mitochondrial damage in the development of diabetic retinopathy

Should women with diabetic nephropathy considering pregnancy continue ACE inhibitor or angiotensin II receptor blocker therapy until pregnancy is confirmed?

Adiponectin reduces thermogenesis by inhibiting brown adipose tissue activation in mice

Pancreatic duct cells as a source of VEGF in mice

Self-monitoring of blood glucose: a promise still unfulfilled?